

Kidney Suite - Committee Meeting 5 Day 1

Date: 19th September 2019

Location: NICE offices London

Minutes: Final

Committee members present:		
Virginia Aylett	Consultant in Medicine for the Elderly, St James's University Hospital, Leeds	Present for all
Tara Bashford	Lay Member	Present for all
Ivan Benett	General Practitioner (Principal),	Present for all
Grainne Connelly	Consultant Chemical Pathologist	Present for all
Jan Dudley (JD)	Consultant Paediatric Nephrologist	Present for all
Deepa Kariywasam	Senior Renal Dietitian	Present for all
Arif Khwaja	Consultant Nephrologist	Present for all
Andrew Lewington	Consultant Renal Physician	Present for all
Fiona Loud	Lay Member	Present for all
Rajib Pal (RP)	General Practitioner (Principle)	Present for all
Catherine Pogson (CP)	Renal Pharmacist	Present for all
Nicola Thomas	Professor of Kidney Care	Present for all
Anthony Wierzbicki (Chair)	Consultant Chemical Pathologist	Present for all

In attendance:		
Chris Carmona (CC)	Senior Technical Analyst	Present for all
Yolanda Martinez (YM)	Analyst - Guideline Updates Team	Present for all
Gail Montrose (GM)	Project Manager	Present for all
Hannah Nicholas (HN)	Technical Analyst	Present for all
Gabriel Rogers (GR)	Technical Adviser	Present for all

Apologies:	
Clare Allinson	Advanced Nurse Practitioner
Justine Karpusheff	NICE - Commissioning Manager

1.

Kidney Suite GComm 5 minutes 19/20.09.19

- Welcome
- Objectives
- Declarations of interest
- Minutes of the last meeting

The Chair welcomed the Committee members and attendees to the first day of the fifth meeting on Kidney Injury & Disease Update.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Finalising the IV Iron review
- RQ 6.1 For people with CKD what eGFR threshold should trigger investigation of anaemia being due to CKD? – Evidence and discussion
- RQ 6.1 For people with CKD what eGFR threshold should trigger investigation of anaemia being due to CKD? – Recommendations and research recommendations
- RQ 7.1 What should be the aspirational Hb target range for children and young people undergoing treatment for anaemia in CKD? – Evidence and discussion
- RQ 7.1 What should be the aspirational Hb target range for children and young people undergoing treatment for anaemia in CKD? - Recommendations and research recommendations
- Further discussion of health economic plan

The Chair asked all committee members to verbally declare any interests that have arisen since the last meeting. The Chair and senior members of the Developer team noted that the interests previously declared, and any new interests did not prevent the attendees from fully participating in the meeting.

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

2. Finalising the IV Iron review

The Chair introduced Yolanda Martinez, Technical Analyst, who presented 'Chronic kidney disease: managing anaemia - IV iron for people who are on dialysis. Finalising the recommendations after committee comments'

The committee discussed the presentation.

The Chair thanked Yolanda Martinez for her presentation.

3. RQ 6.1 Evidence and discussion

4. RQ 6.1 Recommendations and research recommendations

RQ 6.1 For people with CKD, what eGFR threshold should trigger investigation of anaemia

Kidney Suite GComm 5 minutes 19/20.09.19

being due to CKD?

The Chair introduced Shreya Sukla, Technical Analyst, who presented the evidence review for RQ 6.1.

The committee discussed the presentation and drafted recommendations.

The Chair thanked Shreya Sukla for her presentation.

5. RQ 7.1 Evidence and discussion

6. RQ 7.1 Recommendations and research recommendations

RQ 7.1 What should be the aspirational Hb target range for children and young people undergoing treatment for anaemia in CKD?

The Chair introduced Shreya Sukla, Technical Analyst, who presented the evidence review for RQ 7.1.

The committee discussed the presentation and drafted the research recommendations

The Chair thanked Shreya Sukla for her presentation.

7. Further discussion of the health economic plan

The Chair introduced Gabriel Rogers, Technical Advisor (HE), and Hannah Nicholas, Technical Analyst (HE) who presented the Health Economic Plan.

The committee discussed the presentation.

The Chair thanked Gabriel Rogers and Hannah Nicholas for their presentation.

8. AOB

No other business was discussed

Kidney Suite - Committee Meeting 5 Day 2

Date: 20th September 2019

Location: NICE offices London

Kidney Suite GComm 5 minutes 19/20.09.19

Minutes: Draft

Committee members present:		
Virginia Aylett	Consultant in Medicine for the Elderly, St James's University Hospital, Leeds	Present for all
Tara Bashford	Lay Member	Present for all
Ivan Benett	General Practitioner (Principal),	Present for all
Grainne Connelly	Consultant Chemical Pathologist	Present for all
Jan Dudley (JD)	Consultant Paediatric Nephrologist	Present for all
Deepa Kariywasam	Senior Renal Dietitian	Present for all
Arif Khwaja	Consultant Nephrologist	Present for all
Andrew Lewington	Consultant Renal Physician	Present for all
Fiona Loud	Lay Member	Present for all
Rajib Pal (RP)	General Practitioner (Principle)	Present for all
Catherine Pogson (CP)	Renal Pharmacist	Present for all
Nicola Thomas	Professor of Kidney Care	Present for all
Anthony Wierzbicki (Chair)	Consultant Chemical Pathologist	Present for Agenda Items 1, 2 & 3

In attendance:		
Chris Carmona (CC)	Senior Technical Analyst	Present for all
Justine Karpusheff (JK)	NICE - Commissioning Manager	Present for all
Yolanda Martinez (YM)	Analyst - Guideline Updates Team	Present for all
Gail Montrose (GM)	Project Manager	Present for all
Hannah Nicholas (HN)	Technical Analyst	Present for all
Gabriel Rogers (GR)	Technical Adviser	Present for all

Apologies:	
Clare Allinson	Advanced Nurse Practitioner

1. <ul style="list-style-type: none">• Welcome• Objectives• Declarations of interest
The Chair welcomed the Committee members and attendees to the second day of the fifth meeting on Kidney Injury & Disease Update.
The Chair informed the Committee that apologies had been received. These are noted

above.

The Chair outlined the objectives of the meeting, which included:

- Phosphate binders for hyperphosphatemia – preliminary evidence and technical queries for committee
- Phosphate binders – health economics
- Ordering of the remaining research questions
- Review protocols for next group of questions

The Chair asked all committee members to verbally declare any interests that have arisen since the last meeting. No new declarations of interest were declared.

2. Phosphate binders for hyperphosphatemia – preliminary evidence and technical queries for committee

RQ5.1: For people with stage 4 or 5 CKD who are not on dialysis, which phosphate binder, calcium and non-calcium based, is most effective in managing serum phosphate and its associated outcomes?

RQ5.2: For people with stage 5 CKD who are on dialysis, which phosphate binder, calcium and non-calcium based, is most effective in managing serum phosphate and its associated outcomes?

The Chair introduced Yolanda Martinez, Technical Analyst, who presented 'Chronic kidney disease (stage 4 or 5): management of hyperphosphatemia'.

The committee discussed the presentation.

The Chair thanked Yolanda Martinez for her presentation.

3. Phosphate binders – Health Economics

4. Committee discussion

The Chair introduced Gabriel Rogers, Technical Advisor (HE), and Hannah Nicholas, Technical Analyst (HE) who presented 'Hyperphosphatemia model inputs'.

The committee discussed the presentation.

The Chair thanked Gabriel Rogers and Hannah Nicholas for their presentation.

5. Ordering of the remaining research questions

The Chair introduced Chris Carmona, Senior Technical Analyst who presented 'Clustered CKD review questions'

The committee discussed the presentation.

The Chair thanked Chris Carmona for his presentation.

Kidney Suite GComm 5 minutes 19/20.09.19

6. AOB

The Chair introduced Chris Carmona, Senior Technical Analyst who presented 'Proposed NICE pathways changes – AKI'.

The committee discussed the presentation and agreed the proposed pathway.

The Chair thanked Chris Carmona for his presentation.

The Chair introduced Gail Montrose, Project Manager who updated the committee regards potential dates for future committee meetings.

The Chair thanked Gail Montrose for the update.

Next phase key dates	
Stakeholder consultation	19/02/2020 – 18/03/2020
Publication	08/07/2020

Date of next meeting: 11th / 12th November 2019

Location of next meeting: NICE Offices, London